Abstract: Non-small cell lung cancer（NSCLC） is a highly prevalent and aggressive disease. In recent years， the long time survival rate of patients with advanced NSCLC remains low despite of advances in surgery， irradiation， chemotherapy and targeted therapy. The aim of immunotherapy is to specifically enhance the immune response directed to the tumor. Many trials have addressed the role of novel immunotherapeutic agents， such as checkpoint inhibitors and antigenspecific tumour vaccines， which has made breakthrough progress in NSCLC. Immunotherapy will be a fundamentally new concept for the treatment of NSCLC.